Telix Pharmaceuticals Limited (TLX)
| Market Cap | 3.52B -40.1% |
| Revenue (ttm) | 803.79M +55.6% |
| Net Income | -7.13M |
| EPS | -0.02 |
| Shares Out | 338.78M |
| PE Ratio | n/a |
| Forward PE | 699.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 432,376 |
| Open | 10.28 |
| Previous Close | 9.80 |
| Day's Range | 10.10 - 10.71 |
| 52-Week Range | 6.28 - 20.00 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 21.13 (+100.47%) |
| Earnings Date | Apr 17, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.13, which is an increase of 100.47% from the latest price.
News
Telix Pharmaceuticals Shares Jump 7% on FDA Nod for Brain Cancer Imaging Agent Amid Strong Revenue Momentum
MELBOURNE, Australia — Telix Pharmaceuticals Ltd. shares surged more than 7% Friday as the Australian radiopharmaceutical company received a key regulatory boost in the United States, highlighting its...
Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
The agency assigned a PDUFA goal date of September 11.
Telix Pharmaceuticals (TLX) Sees 7% Gain Following FDA Acceptance of Imaging Agent
Telix Pharmaceuticals (TLX) Sees 7% Gain Following FDA Acceptance of Imaging Agent
ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA Nod as Healthcare Leads Mixed Session Amid Oil Rebound
SYDNEY — Telix Pharmaceuticals Ltd (ASX: TLX) led the S&P/ASX 200 gainers Friday with a 3.23 percent surge to $14.08 after the U.S. Food and Drug Administration accepted its resubmitted New Drug Appli...
FDA Accepts NDA for TLX101-Px (Pixclara®)
MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Adm...
Telix Strengthens Board with Additional Director Appointments
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) app...
Why Is Telix Pharma Stock Soaring Tuesday?
Wedbush analyst David Nierengarten reiterated an Outperform rating on the stock and maintained a $22 price target, underscoring confidence in Telix's growth trajectory.
Telix Pharmaceuticals Stock Rises 5% Over Strong Revenue Growth In Q1
(RTTNews) - Shares of Telix Pharmaceuticals Limited (TLX) are moving up about 5 percent after the company announced first-quarter financial results, which saw 24% increase in revenue to $230 million f...
Telix Pharma Reports 24% Revenue Growth In Q1; Stock Up
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a commercial-stage company, reported first-quarter results on Monday, reflecting 24% revenue growth compared to the prior year. In addition, the firm r...
Telix Pharmaceuticals Q1 Group Revenue Rises; Stock Up
(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) reported that its group revenue for the first quarter of fiscal year 2016 increased about 24% to US$230 million, from US$186 million last year.
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational perf...
Telix Appoints David Gill as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executiv...
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical prod...
Telix Resubmits NDA For Brain Cancer Imaging Candidate TLX101-Px To FDA
(RTTNews) - Telix Pharmaceuticals Limited (TLX) announced that it has resubmitted the NDA to the United States Food and Drug Administration or FDA for its investigational imaging agent TLX101-Px(Pixcl...
Telix Resubmits TLX101-Px NDA To FDA For Brain Cancer Imaging Agent
(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TLX101-Px (Pixclara, Floretyrosi...
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA...
Why Is Telix Pharmaceuticals Stock Gaining Tuesday?
Telix Pharma's ProstACT study achieves primary objectives, positioning TLX591-Tx as potential first-line treatment for prostate cancer. Full story available on Benzinga.com
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 stud...
Telix Pharmaceuticals Ltd at TD Cowen Healthcare Conference Transcript
Telix Pharmaceuticals Ltd at TD Cowen Healthcare Conference Transcript
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospita...
1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth
Telix's revenue grew by 56% in 2025. The Australian company develops drugs that can both detect and treat cancers.
Citigroup Raises Price Target on Telix Pharmaceuticals (TLX) to $22.50 | TLX Stock News
Citigroup Raises Price Target on Telix Pharmaceuticals (TLX) to $22.50 | TLX Stock News
Telix Pharmaceuticals Ltd (TLPPF) Full Year 2025 Earnings Call Highlights: Robust Revenue ...
Telix Pharmaceuticals Ltd (TLPPF) Full Year 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic R&D Investments
Full Year 2025 Telix Pharmaceuticals Ltd Earnings Call Transcript
Full Year 2025 Telix Pharmaceuticals Ltd Earnings Call Transcript
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended Decembe...